MetaboGen is granted US diabetes patent
MetaboGen AB has on January 30th, 2018 been granted a US patent for the identification of a person at risk for developing type 2 diabetes using metagenomic sequence data from the GI-tract.
The human intestinal tract is inhabited by 10-100 trillion of microbes comprised of thousands of different species, collectively called the microbiota. This microbial community has an immense capacity to affect host biology. Imbalance in the gut microbiome is associated with multiple diseases and unhealthy conditions. The microbiome thus holds great potential to provide the industry with new opportunities to understand and tackle health issues for the benefit of patients.
– We are very pleased to have been granted this patent in the important diabetes area, Sara Malcus, CEO of MetaboGen says.
Read the full press release here:
MetaboGen Press release Feb 12 2018